US FTC Continues Aggressive Scrutiny of Pharmaceutical Patents Listed in the Orange Book

On April 30, 2024, the US Federal Trade Commission (“FTC”) announced that it had sent “warning letters” to 10 branded pharmaceutical manufacturers, alleging that the companies had made “improper or inaccurate listing of patents” in the Food and Drug Administration’s (“FDA”) “Orange Book.”…
By: Mayer Brown
Previous Story

Federal Trade Commission Continues to Target Healthcare Companies for Unauthorized Data Disclosures

Next Story

Data Privacy + Cybersecurity Insider – May 2024 #2